368
Views
21
CrossRef citations to date
0
Altmetric
Original Article

Socio-demographic, clinical and treatment characteristics of relapsing schizophrenic patients

, M.D., Ph.D., , M.D., Ph.D., , M.D., Ph.D., , Ph.D., , Ph.D. & , M.D.
Pages 22-29 | Accepted 13 Feb 2012, Published online: 20 Mar 2012
 

Abstract

Aims: To define the clinical profile of relapsing patients with schizophrenia attended in daily practice. Method: Patients with schizophrenia/schizoaffective disorder admitted to short-stay/acute-care psychiatric units were eligible provided that data for the previous 3 years and for the next 12 months after discharge were collected. Results: Remarking features in 1646 patients (68% men) included low family support (34%), primary education (48%), schizophrenia as the main diagnosis (77%), duration of illness > 10 years (60%), mean number of previous hospitalizations of 2.74, non-adherence as the main reason of hospitalization (58.6%), treatment with a mean of two different antipsychotics and differences in adherence according to antipsychotic medication (P < 0.0001) (highest rates for depot atypical antipsychotics). The relapse rate was 38.6%. There were no differences in the number of relapsing patients according to antipsychotic drugs. Discussion and conclusion: The profile of relapsing schizophrenic patients may be defined as a male subject, aged 30–45 years, with primary education level, more than 10 years of disease’ duration, low family support, moderately and severely ill, treated with multiple antipsychotic drugs, and poor to moderate adherence. Differences in relapse according to antipsychotic types were not observed but long-acting second generation antipsychotic drugs showed the highest percentage of maximum adherence.

Acknowledgements

The authors thank Content’Ed Net Communications, S.L., for editorial assistance and Marta Pulido, M.D., for editing the manuscript.

Declaration of interest: P. Martínez, B. González and M. Peña are employees of Janssen-Cilag Spain. The authors alone are responsible for the content and writing of the paper.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.